Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT00731224
- Locations
- 🇹🇷
Novartis Investigative Site, Uskudar / Istanbul, Turkey
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT00728351
- Locations
- 🇫🇷
Polycliniques des minguettes, Venissieux, France
🇩🇪Malteser KM, Duisburg, Germany
🇩🇪Diabeteszentrum Billstedt/Horn, Hamburg, Germany
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1110
- Registration Number
- NCT00720941
- Locations
- 🇬🇧
Novartis Investigative Site, Swansea, United Kingdom
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
- Conditions
- Nephroid CarcinomaAdenocarcinomaRenal CellHypernephroidCarcinoma
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 365
- Registration Number
- NCT00719264
- Locations
- 🇺🇸
City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(3), Duarte, California, United States
🇺🇸USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States
🇺🇸University of California at Los Angeles Dept. of Hem/Oncology, Los Angeles, California, United States
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
- Conditions
- Post-menopausal Osteoporosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT00718861
- Locations
- 🇹🇭
Novartis Investigative Site, Khonkaen, Thailand
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00718562
- Locations
- 🇯🇵
Novartis Investigative Site, Chuo-ku, Tokyo, Japan
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT00715182
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
- Conditions
- Neoplasms, Breast
- Interventions
- Drug: Lapatinib/nab-Paclitaxel
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00709761
- Locations
- 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT00708292
- Locations
- 🇺🇸
Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale, Arizona, United States
🇺🇸Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio, Texas, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 203
- Registration Number
- NCT00704678
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan